Ipamorelin · Research brief

How Many Doses Per Vial Ipamorelin? (Concentration Guide)

Real Peptides Research TeamEditorial

Updated April 9, 20269 min read

40 WORDS

Short answer

Key takeaways

A 5mg ipamorelin vial reconstituted with 2mL bacteriostatic water yields 10–25 doses depending on target dose, with practical yield reduced by 1–2 doses due to unavoidable dead volume in the vial.
Reconstitution concentration is calculated as total peptide mass (mcg) divided by bacteriostatic water volume (mL). A 5mg vial with 2mL water produces 2,500mcg/mL concentration.
Most research protocols use 200–300mcg per dose twice daily, meaning a single 5mg vial lasts 7–10 days, not the 2–3 weeks researchers often assume.
Reconstituted ipamorelin maintains >95% potency for 28 days when refrigerated at 2–8°C, but any temperature excursion above 8°C causes irreversible peptide degradation that cannot be detected visually.
Higher reconstitution volumes (2mL vs 1mL) improve syringe measurement accuracy for small doses but reduce shelf life slightly due to increased oxidation surface area.

A single 5mg vial of ipamorelin doesn't contain a fixed 'number of doses'. It contains 5,000 micrograms of lyophilized peptide that yields anywhere from 10 to 25 usable doses depending on how you reconstitute it and what dose you're targeting. The vial itself is inert until you add bacteriostatic water, and the concentration you create during reconstitution determines how many actual doses you extract. Researchers who assume 'one vial equals ten doses' without accounting for reconstitution volume routinely miscalculate their protocol timelines and run out of peptide mid-cycle.

Our team has guided hundreds of research labs through peptide reconstitution protocols. The gap between doing it right and doing it wrong comes down to three things most suppliers never explain: reconstitution math, syringe precision, and storage degradation.

How many doses are in a 5mg vial of ipamorelin?

A 5mg ipamorelin vial reconstituted with 2mL bacteriostatic water yields 10 doses at 500mcg each, 16 doses at 300mcg each, or 25 doses at 200mcg each. The dose count depends entirely on your target dose per injection and the total reconstitution volume. Not the vial size. Most research protocols use 200–300mcg per dose, which puts the practical yield at 16–25 doses per 5mg vial when reconstituted with 2mL of bacteriostatic water.

Understanding Ipamorelin Concentration and Reconstitution

Ipamorelin vials from research suppliers arrive as lyophilized powder. Meaning the peptide has been freeze-dried into a stable crystalline form that contains zero liquid. The listed 'milligram amount' (5mg, 10mg, 15mg) refers to the mass of peptide present in the vial, not volume. Until you reconstitute it with bacteriostatic water, there is no concentration to measure and no doses to extract.

Reconstitution math follows this formula: Final Concentration (mcg/mL) = Total Peptide Mass (mcg) ÷ Reconstitution Volume (mL). A 5mg vial contains 5,000mcg. If you add 2mL of bacteriostatic water, the concentration becomes 5,000mcg ÷ 2mL = 2,500mcg/mL. Each 0.1mL drawn from that vial delivers 250mcg. If your target dose is 300mcg, you'd draw 0.12mL per injection. Which means that 2mL reconstituted vial yields approximately 16 doses (2mL ÷ 0.12mL = 16.6 doses).

The choice of reconstitution volume directly impacts syringe precision. Adding 1mL instead of 2mL doubles the concentration to 5,000mcg/mL. Now each 0.1mL contains 500mcg instead of 250mcg. For researchers targeting small doses (100–200mcg), higher concentration forces you to measure volumes as small as 0.02–0.04mL on an insulin syringe, where measurement error exceeds 10%. We consistently recommend 2mL reconstitution for 5mg vials because it balances concentration precision with manageable syringe measurements.

Dose Count Calculation Across Common Protocols

Most ipamorelin research protocols target doses between 200mcg and 500mcg per administration, typically twice daily. A 5mg vial reconstituted with 2mL bacteriostatic water (concentration: 2,500mcg/mL) yields dramatically different dose counts depending on target dose:

500mcg dose: 0.2mL per injection → 10 total doses from a 2mL vial
300mcg dose: 0.12mL per injection → 16 total doses from a 2mL vial
250mcg dose: 0.1mL per injection → 20 total doses from a 2mL vial
200mcg dose: 0.08mL per injection → 25 total doses from a 2mL vial

These calculations assume zero waste, which is unrealistic. Every reconstitution leaves approximately 0.1–0.15mL 'dead volume' trapped in the vial that cannot be drawn even with a 31-gauge insulin syringe. Practical yield drops by 1–2 doses per vial once you account for this. A researcher running a 300mcg protocol should plan for 14–15 usable doses per 5mg vial, not 16.

Protocol duration depends on dosing frequency. If you're administering 300mcg twice daily (a common saturation dose schedule), a single 5mg vial lasts 7–8 days. Researchers often underestimate vial consumption because they calculate based on total milligrams without factoring in dead volume and twice-daily administration. A 12-week protocol at 300mcg twice daily requires approximately 12 vials. Not the 6 vials you'd expect from naive math.

Storage Duration and Peptide Stability Post-Reconstitution

Once reconstituted, ipamorelin degrades continuously. Even under optimal refrigeration. Bacteriostatic water extends usability beyond sterile water (which allows bacterial growth within 48 hours), but it doesn't stop peptide oxidation. Research-grade ipamorelin stored at 2–8°C in bacteriostatic water maintains >95% potency for approximately 28 days, after which degradation accelerates.

Temperature excursions are the silent killer of reconstituted peptides. A single 4-hour period above 8°C. Common during shipping or temporary refrigerator failure. Triggers irreversible aggregation of peptide chains. The solution may still appear clear, but potency drops by 15–30%. There is no at-home test for peptide integrity; researchers who notice 'reduced effects' weeks into a protocol are often working with degraded product without realizing it.

Freezing reconstituted peptides is controversial. Lyophilized powder tolerates freezing at −20°C indefinitely, but once mixed with bacteriostatic water, ice crystal formation during freezing can denature the peptide structure. Some protocols freeze individual aliquots in cryovials to extend shelf life beyond 28 days, but this introduces a freeze-thaw risk each time an aliquot is used. Our team recommends against freezing reconstituted ipamorelin unless you're working with specialized cryoprotectants like glycerol. And even then, expect 5–10% potency loss per freeze-thaw cycle.

What If: Ipamorelin Dosing Scenarios

What If I Reconstitute a 5mg Vial with 1mL Instead of 2mL?

You double the concentration to 5,000mcg/mL, which halves the volume you need to draw per dose. A 300mcg dose now requires only 0.06mL instead of 0.12mL. The problem: insulin syringes struggle to measure volumes below 0.05mL accurately. Measurement error at this scale exceeds 10%, which means your actual dose could range from 270mcg to 330mcg. Higher concentration also increases the risk of injection site reactions because you're delivering the same peptide mass in half the volume. Use 1mL reconstitution only if you're targeting doses above 400mcg where draw volumes remain above 0.08mL.

What If I Need to Travel Mid-Protocol with Reconstituted Ipamorelin?

Reconstituted peptides must stay between 2–8°C continuously. Most travel medical coolers maintain this range for 36–48 hours using gel packs, but anything marketed as a 'lunchbox cooler' won't cut it. You need a purpose-built medication cooler with verified temperature stability. The FRIO wallet uses evaporative cooling and works without ice or electricity, maintaining 18–26°C ambient storage, which is acceptable for short trips (under 24 hours) but not ideal for extended travel. If you're traveling longer than 48 hours, consider bringing lyophilized powder and reconstituting on-site instead of transporting pre-mixed vials.

What If My Vial Looks Cloudy After Reconstitution?

Discard it immediately. Properly reconstituted ipamorelin should be crystal clear with no visible particles, cloudiness, or discoloration. Cloudiness indicates one of three failures: bacterial contamination (rare with bacteriostatic water but possible if the rubber stopper was compromised), peptide aggregation from improper mixing technique (shaking instead of gentle swirling), or receipt of degraded product. Never inject cloudy peptide solutions. The risk of injection site abscess or systemic reaction isn't worth salvaging a $40 vial.

The Unvarnished Truth About Ipamorelin Vial Economics

Here's the honest answer: most researchers waste 20–30% of their peptide investment through poor reconstitution planning and storage mistakes. Not contamination. Not incorrect dosing. Just basic math errors and temperature mismanagement.

The single biggest mistake is ordering vials based on 'total milligrams needed' without accounting for reconstitution dead volume and twice-daily protocols. A researcher calculates '12 weeks at 300mcg per day equals 25,200mcg total, so I need five 5mg vials'. But that assumes one dose per day and zero waste. The reality: 300mcg twice daily for 12 weeks requires 50,400mcg total peptide, plus 15% waste from dead volume and degradation past 28 days, which means you actually need eleven 5mg vials. Underordering forces mid-protocol reorders that disrupt consistency.

The second mistake is reconstituting entire vials when protocols call for infrequent dosing. If you're running a 200mcg once-daily protocol, a 2mL-reconstituted 5mg vial lasts 25 days. But potency starts declining after day 28. You'll use 22–23 doses before degradation becomes noticeable, wasting 2–3 doses per vial. Smaller vials (2mg or 3mg) reconstituted with 1mL match better with low-frequency protocols, even though per-milligram cost is slightly higher.

Storage discipline matters more than syringe precision. A peptide stored at 10°C degrades 40% faster than one stored at 4°C. Researchers who keep reconstituted vials in the refrigerator door (where temperature fluctuates 2–3°C every time it opens) consistently report 'weaker effects' in week three compared to week one. That's degradation, not tolerance. Store vials on the bottom shelf toward the back, away from the door and the freezer vent.

Ipamorelin purchased from verified research suppliers like Real Peptides undergoes amino acid sequencing verification and HPLC purity testing at >98%. Which means when you calculate doses per vial, you're working with actual peptide content, not filler or degraded product. Lower-cost suppliers often ship peptides at 85–90% purity, which throws off all concentration math and forces you to use 10–15% more volume per dose to achieve the same effect.

Anyone working with peptides long-term eventually hits this realization: the cost isn't in the vial. It's in the waste from poor handling. A $45 vial that delivers 16 usable doses costs $2.81 per dose. That same vial stored poorly, reconstituted incorrectly, or left at room temperature for six hours costs $3.75 per dose after accounting for the 25% you'll throw away. Multiply that across a 12-week protocol and the difference is $50–$80 in wasted peptide.

Protocol consistency beats dosing precision every time. Researchers obsess over drawing exactly 0.12mL instead of 0.11mL, then store their vials at 12°C and wonder why results plateau. Temperature stability, reconstitution math, and dead volume planning determine whether you get 14 usable doses or 16 from the same vial. Syringe precision is tertiary.

Closing Paragraph

The question 'how many doses per vial' has no single answer because ipamorelin vials don't contain doses. They contain peptide mass that you convert into doses through reconstitution. A researcher who understands concentration math, accounts for dead volume, and maintains strict refrigeration extracts 15–20% more usable doses from the same vial compared to someone who reconstitutes haphazardly and stores inconsistently. That gap compounds across every vial in a 12-week protocol, turning what should be an eleven-vial study into a thirteen-vial study purely through handling errors. The mechanics aren't complicated, but the cost of ignoring them shows up in every dose you throw away.

Questions

A 5mg vial reconstituted with 2mL bacteriostatic water yields 10–25 doses depending on your target dose per injection. At 200mcg per dose, you get approximately 25 doses; at 300mcg per dose, approximately 16 doses; at 500mcg per dose, approximately 10 doses. Practical yield is 1–2 doses lower due to dead volume that cannot be drawn from the vial.

Sterile water lacks the benzyl alcohol preservative that prevents bacterial growth, so reconstituted peptides must be used within 48–72 hours or refrigerated in single-use aliquots. Bacteriostatic water extends usability to 28 days under refrigeration. Most research protocols spanning multiple weeks require bacteriostatic water to avoid daily reconstitution and the contamination risk that comes with repeated vial access.

Injecting air creates positive pressure inside the vial, which forces peptide solution back through the needle when you withdraw the syringe — this pulls contaminants into the vial and increases infection risk on subsequent draws. Always equalize pressure by drawing an equivalent volume of air out before injecting bacteriostatic water, or inject water slowly while allowing air to escape through a vented needle.

Degraded ipamorelin may appear cloudy, discolored (yellow or brown tint), or contain visible particles, but some degradation occurs without visual change. The most reliable indicator is reduced effect compared to earlier doses from the same vial. Any cloudiness, discoloration, or particulate matter is grounds for immediate disposal — never inject visibly degraded peptide solutions regardless of storage timeline.

Refrigerate immediately after reconstitution and gentle mixing. Allowing reconstituted peptides to sit at room temperature accelerates oxidation and bacterial growth. The peptide solution reaches usable state within 10–15 minutes of mixing at refrigeration temperature — there is no benefit to room-temperature equilibration and measurable risk of potency loss during that window.

Combining peptides in one vial (often called ‘blending’) changes the pH, osmolality, and degradation rate of both compounds in unpredictable ways. Some combinations are stable (CJC-1295 + ipamorelin is commonly pre-blended by suppliers), but others precipitate or degrade rapidly. Never mix peptides yourself unless you have verified stability data for that specific combination — use separate vials and administer sequentially instead.

Larger vials (10mg, 15mg) offer lower per-milligram cost but require higher reconstitution volumes or faster usage to prevent degradation past 28 days. A 5mg vial suits protocols under 300mcg twice daily; 10mg vials suit higher-dose or extended protocols. The break-even point is around 16–20 doses per vial — if your protocol uses fewer than 16 doses in 28 days, smaller vials reduce waste despite higher per-milligram cost.

Approximately 0.1–0.15mL of solution remains trapped at the bottom of a standard peptide vial even with optimal syringe technique. For a 2mL reconstituted 5mg vial at 2,500mcg/mL concentration, this represents 250–375mcg of unusable peptide — equivalent to 1–2 full doses depending on your target dose. This is unavoidable with current vial designs and should be factored into protocol planning.

2mL reconstitution produces 2,500mcg/mL concentration, which allows accurate measurement of small doses (200–300mcg) using standard insulin syringes. 1mL reconstitution doubles concentration to 5,000mcg/mL, which improves slightly for high-dose protocols (500mcg+) but makes small-dose measurement prone to 10–15% error. For most research applications targeting 200–400mcg doses, 2mL reconstitution balances precision and usability.

Freezing reconstituted peptides in cryovials can extend stability beyond 28 days, but ice crystal formation during freezing denatures 5–10% of peptide structure per freeze-thaw cycle. This approach works for bulk protocols where slight potency loss is acceptable, but requires cryoprotectants like glycerol for optimal results. Most researchers find it more reliable to order appropriately sized vials that match their 28-day usage window rather than managing frozen aliquots.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA